Viz.ai has announced a partnership with Alnylam Pharmaceuticals to improve early identification and care coordination for patients with cardiac amyloidosis, a progressive and frequently underdiagnosed cause of heart failure. The collaboration focuses on deploying an AI-enabled care pathway designed to identify patients earlier and guide clinicians through standardized diagnostic and treatment processes.
Cardiac amyloidosis occurs when misfolded proteins accumulate in the heart muscle, impairing function and leading to poor outcomes if untreated. The condition includes two primary forms: transthyretin-mediated amyloidosis (ATTR-CM) and light chain amyloidosis (AL). Despite therapeutic advances, diagnosis is often delayed due to nonspecific symptoms and fragmented care pathways.
“Cardiac amyloidosis is a condition where delayed diagnosis has real consequences in heart failure – earlier identification can fundamentally alter a patient’s trajectory,” said Tim Showalter, MD, Chief Medical Officer of Viz.ai. “This partnership is about making early detection actionable. By combining advanced imaging and generative AI with a care coordination platform, we will help clinicians find the right patients earlier and move them swiftly toward appropriate care before the window for meaningful intervention narrows.”
The new AI Care Pathway integrates an FDA-cleared echocardiography algorithm, Us2.ai, with electronic health record connectivity and generative AI capabilities. The system is designed to automatically analyze standard echocardiograms, flag patients with suggestive indicators, and coordinate next steps such as confirmatory testing, specialist referral, and follow-up across cardiology and heart failure teams.
By embedding guideline-based recommendations directly into clinical workflows, the platform aims to reduce variability in care and support more consistent, evidence-based decision-making.
“ATTR-CM is recognized late far too often, after patients have spent years searching for answers while the disease silently progresses,” said Sameer Bansilal, M.D., M.S., Cardiologist and Vice President, Global TTR Medical Lead, Alnylam Pharmaceuticals. “By partnering with Viz.ai, we are bringing AI into everyday clinical decision-making, helping clinicians detect warning signs earlier, initiate appropriate diagnostic testing sooner, and ultimately deliver more timely, coordinated care for patients.”
The solution will be evaluated through a multi-site pilot study assessing its impact on diagnostic timelines, treatment initiation, and care coordination. The initiative expands the Viz Cardio Suite™, part of a broader platform currently deployed in approximately 2,000 hospitals across the United States.
Click here for the original news story.